To determine if the siRNA-knockdown of TIGAR expression could sensitize hrHPV-infected cervical cancer cells to otherwise sub-inhibitory concentrations of doxorubicin, HPV18-transformed HeLa cells or immortalized human HFL1 fibroblasts were transfected with 25 ng of either siRNA-TIGAR or a scrRNA oligonucleotide as a negative control and then, after 24 hrs, treated with various concentrations (0.05, 0.1, or 0.2 μM) of doxorubicin. The gene discussed is TIGAR; the disease is cervical cancer.